PHILADELPHIA – Genetic counseling for cancer patients has become standard of care at academic medical centers, but patients cared for at community-based medical practices across the United States may not have access to these resources. Video and phone sessions can close that gap and bring genetic counseling to patients who would not otherwise have the chance to receive it, according to a new study from the Basser Center for BRCA at the University of Pennsylvania’s Abramson Cancer Center.
Researchers conducted a randomized, controlled trial to determine whether patients at community practices would undergo genetic testing after a remote phone or video counseling session and found 77 percent of patients chose to do so, compared to just six percent in the group of patients that were offered usual care options for genetic testing, such as driving to a center with genetic counselor or having genetic testing with their doctor and without the assistance of a genetics professional. The study’s lead author, Angela R. Bradbury, MD, an assistant professor of Hematology-Oncology, will present the findings at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6506).
Germline genetic testing helps doctors identify patients at increased risk for cancer who may benefit from additional or early screening or other cancer prevention interventions. This testing includes detection of BRCA mutations, which are linked to a drastically increased lifetime risk of breast and ovarian cancers, as well as pancreatic and prostate cancer. Genetic counselors work as part of a patient’s healthcare team and can help patients and providers understand how genetic and familial risk contribute to cancer risk, they can make recommendations for the most appropriate genetic testing and provide guidance on how to understand genetic results and what they mean for a patient’s healthcare. Currently, only 37 percent of patients who undergo testing meet with a counselor beforehand.
Bradbury and her team randomly assigned 115 patients who were candidates for genetic testing into two groups – one that received a phone or video counseling session and one that were provided information on how they can get genetic testing. All participants were patients at primary care practices throughout Pennsylvania, New Jersey, Delaware, and Maryland.
Of the 71 patients in the group offered remote genetic counseling services, 55 of them (77 percent) went on to complete the counseling. Just two of 36 patients (six percent) in the usual care group completed genetic counseling. In addition, 55 percent of patients in the remote services arm proceeded to actual genetic testing, leading to the identification of four genetic carriers. Only 17 percent of patients in the usual care arm underwent testing, and no carriers were identified.
“The data definitively show the impact of remote genetic services, and it’s clear from this study that this telemedicine approach improves on what community practices can do on their own,” Bradbury said. “That said, it’s noteworthy that just 56 percent of patients who underwent remote counseling went on to undergo genetic testing. It shows we still have work to do to help equip patients with this information, which can be life-saving in some cases.”
Bradbury also noted another important area to address: the discrepancy between patients in the usual care arm who underwent counseling and those who underwent testing.
“The data confirm that some people in community practices are getting testing without going through counseling first, and previous studies have shown that patients have lower levels of knowledge and lower satisfaction when that happens,” Bradbury said.
The study also compared the effectiveness of the two telemedicine options and preliminary findings suggest that videoconference leads to a greater increase in knowledge and a greater decrease in depression when compared to baseline than phone sessions. The authors note this finding is preliminary and points to a need for further research.
Susan M. Domchek, MD, executive director of the Basser Center for BRCA, was a co-investigator on the study, which was supported by the Basser Center for BRCA.
Bradbury will present the findings as an oral abstract in the Health Services Research, Clinical Informatics, and Quality of Care session on Friday June 1st at McCormick Place in Room S404 at 4:45 Central.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.